ForskolinvsNicotine

Forskolin directly activates all nine isoforms of membrane-bound adenylate cyclase (AC1-9), the enzyme that converts ATP to cyclic AMP (cAMP), bypassing G-protein-coupled receptor activation. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) at Ser133 — a transcription factor essential for long-term memory formation that induces expression of BDNF, c-fos, and other plasticity-related genes. This is the same signaling cascade used by dopamine (D1), norepinephrine (beta-adrenergic), and serotonin (5-HT4/7) receptors, but forskolin activates it directly at the effector level. Elevated cAMP also increases neurotransmitter receptor sensitivity (e.g., beta-adrenergic receptor phosphorylation), enhances synaptic plasticity via PKA-mediated GluA1 phosphorylation, and potentiates L-type calcium channels. Forskolin may also activate TRPV channels.

Nicotine binds to nicotinic acetylcholine receptors (nAChRs), particularly the high-affinity alpha-4-beta-2 subtype predominant in the brain, causing conformational changes that open the cation channel and allow Na+ and Ca2+ influx, depolarizing the neuron. This triggers vesicular release of dopamine (VTA to nucleus accumbens and prefrontal cortex), norepinephrine (locus coeruleus), acetylcholine (basal forebrain), serotonin, and glutamate. Cognitive enhancement comes from increased acetylcholine in the prefrontal cortex and hippocampus (attention, working memory) and dopamine in mesocortical pathways (motivation, executive function). Nicotine upregulates BDNF through nAChR-mediated Ca2+ signaling and CREB activation, and has anti-inflammatory effects via microglial alpha-7 nAChRs. Neuroprotection may involve reduced excitotoxicity and enhanced neuronal survival pathways.